isoxazoles has been researched along with Metabolic Syndrome in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC | 1 |
| Ballot, C; Decoster, B; Hassoun, SM; Lancel, S; Marciniak, C; Marechal, X; Montaigne, D; Neviere, R; Palud, A | 1 |
| Alawad, AS; Levy, C | 1 |
| Arita, E; Auwerx, J; Horai, Y; Houten, SM; Itoh, H; Mataki, C; Morimoto, K; Sato, H; Schoonjans, K; Sugizaki, T; Tanigawara, Y; Watanabe, M | 1 |
| Aadamsoo, K; Bergmans, P; Fernández, LG; Hoeben, D; Korcsog, P; Niehaus, D; Salinas, R; Schreiner, A; Shuriquie, NA; Tessier, C; Theodoropoulou, P; Uçok, A | 1 |
| Ahn, YM; Jung, HY; Kim, CE; Kim, WH; Kim, YS; Min, KJ; Na, KS; Park, KC; Ryu, SG; Yoon, JS | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
2 review(s) available for isoxazoles and Metabolic Syndrome
| Article | Year |
|---|---|
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
1 trial(s) available for isoxazoles and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Delayed-Action Preparations; Female; Glucose Tolerance Test; Humans; Isoxazoles; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Triglycerides; Waist Circumference | 2012 |
4 other study(ies) available for isoxazoles and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Advanced Oxidation Protein Products; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Case-Control Studies; Disease Progression; Female; Gene Expression; Humans; Isoxazoles; Leflunomide; Lipid Peroxides; Male; Metabolic Syndrome; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Sex Factors; Uric Acid | 2018 |
Macrophage migration inhibitory factor inhibition is deleterious for high-fat diet-induced cardiac dysfunction.
Topics: Animals; Carbohydrate Metabolism; Cardiomyopathies; Diet, High-Fat; Energy Metabolism; Female; Gene Expression Regulation; Glucose; Isoxazoles; Lipid Metabolism; Macrophage Migration-Inhibitory Factors; Metabolic Syndrome; Mice; Mitochondria; Myocardium; Oxygen Consumption | 2013 |
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
Topics: 3T3-L1 Cells; Animals; Bile Acids and Salts; Body Weight; Diabetes Mellitus; Dietary Fats; Energy Metabolism; Isoxazoles; Metabolic Syndrome; Mice; Obesity; Receptors, Cytoplasmic and Nuclear | 2011 |
Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inflammation; Isoxazoles; Leukocyte Count; Male; Metabolic Syndrome; Middle Aged; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2012 |